title: Effect of tamsulosin on systemic blood pressure and nonneurogenic dysfunctional voiding in children.
abstract: OBJECTIVE
  A number of therapies for dysfunctional voiding in children have been proposed after conservative measures have failed. Prior studies have shown significant improvement in lower urinary tract symptoms with alpha1-adrenergic antagonists. Nonselective alpha1-adrenergic antagonists can result in systemic vasodilatation and hypotension. We examined the effects of tamsulosin, a uroselective alpha1A-adrenergic antagonist, on blood pressure, as well as its safety and efficacy in the treatment of dysfunctional voiding in a pediatric population.
  
  
  METHODS
  A total of 23 children without anatomical or neurogenic abnormalities presented with lower urinary tract symptoms refractory to conservative measures. All children had increased post-void residual urine or abnormal uroflowmetry in the absence of pelvic floor activity suggestive of bladder neck dysfunction. All patients were administered tamsulosin daily. Voiding diaries, blood pressure, uroflowmetry studies and patterns along with assessment of post-void residual urine were obtained before and after beginning tamsulosin in all children.
  
  
  RESULTS
  Median duration of tamsulosin therapy was 7 months, and patient followup was 20 months. The number of voiding and incontinent episodes significantly decreased during treatment compared to baseline (p <0.05). Mean blood pressures before and during tamsulosin treatment were 98/55 mm Hg and 110/61 mm Hg, respectively. Significant increases in average and maximum urinary flow rates along with reduction in post-void residual urine were observed during tamsulosin therapy compared to baseline values (p <0.01). A 50% reduction in the number of abnormal uroflow patterns was observed with tamsulosin therapy.
  
  
  CONCLUSIONS
  Tamsulosin demonstrated no clinically significant effect on blood pressure, while proving to be a safe and effective treatment option for lower urinary tract symptoms in a select pediatric population.
authors.affiliation: Division of Pediatric Urology, Schneider's Children Hospital and Smith Institute for Urology, North Shore Long Island Jewish Health System, New Hyde Park, New York, USA.
authors.forename: Brian A
authors.initials: BA
authors.lastname: Vanderbrink
authors.forename: Jordan
authors.initials: J
authors.lastname: Gitlin
authors.forename: Sylvia
authors.initials: S
authors.lastname: Toro
authors.forename: Lane S
authors.initials: LS
authors.lastname: Palmer
mesh_terms: D000293:Adolescent; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D001795:Blood Pressure Determination; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011336:Probability; D012189:Retrospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D013449:Sulfonamides / Q000627:therapeutic use*; D000077409:Tamsulosin; D016896:Treatment Outcome; D016055:Urinary Retention / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000209:etiology / Q000517:prevention & control; D014555:Urination Disorders / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D014563:Urodynamics
chemical_list: D000317:Adrenergic alpha-Antagonists; D013449:Sulfonamides; D000077409:Tamsulosin